ClinicalTrials.gg
WithdrawnNCT02392676Updated May 2, 2016

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

A Phase 3 interventional study of OLAPARIB and PLACEBO in Platinum Sensitive Relapsed Ovarian Cancer, sponsored by AstraZeneca. Withdrawn at 29 sites in 5 countries. Open to female participants aged 18 Years to 96 Years. Per ClinicalTrials.gov, last updated 2016-05-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 96 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
65th of 69
0 · median 97
Started
2016
with 4 others
Phase 3
16 of 69
2 open now
Registered
17th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 65th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 17th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 96 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations or loss of function (deleterious or suspected deleterious) mutation in non-BRCA Homologous Recombination Repair (HRR) -associated genes who have a complete or partial response to platinum-based chemotherapy.

Read the detailed description

This is a phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) who have responded following platinum based chemotherapy. The study population will be enrolled as two separate cohorts that will enrol simultaneously. The confirmatory cohort will consist of patients who carry a somatic BRCA mutation (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious) which are detected in tumour material but absent from germline blood testing ; the exploratory cohort will include patients with a mutation (documented mutation predicted to be deleterious or suspected deleterious) in non BRCA HRR-associated genes which are detected in tumour material regardless of their germline status.

03

Conditions studied

  • Platinum Sensitive Relapsed Ovarian Cancer

Browse trials for

Keywords

  • Ovarian cancer
  • Platinum
  • Somatic BRCA mutation
  • Homologous recombination repair
04

Who can participate

Ages eligible
18 Years to 96 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age
  • diagnosed high grade epithelial ovarian cancer (including primary peritoneal and/ or fallopian tube cancer)
  • Documented deleterious or suspected deleterious somatic BRCA 1 and/or BRCA 2 somatic mutation or evidence of non- BRCA HRR-associated gene mutation in the tumour.
  • At least 2 previous lines of platinum containing therapy prior to randomisation.
  • CA-125 measurements prior to randomised treatment
  • Patients must have normal organ and bone marrow function measured within 28 days of randomisation
  • (ECOG) performance status 0-1
  • or evidence of non-childbearing status for women of
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
  • Provision of a blood sample for cfDNA biomarker analysis in Pre-Screening Part 1
  • Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary or recurrent cancer must be available for central testing. If is not available tumour sample from fresh biopsy is acceptable, for all patients eligible to participate in Pre-Screening part 2.

Exclusion criteria

Exclusion Criteria:

  • Documented germline mutation in BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
  • Patients who have had drainage of their ascites from the final 2 cycles of their last chemotherapy regimen prior to randomisation on the study
  • Participation in another clinical study with an product during the chemotherapy course immediately prior to randomisation
  • Any previous treatment with a PARP inhibitor, including olaparib
  • Patients with a known to olaparib or any of the of the product
  • Prior in the last 5 years, unless curatively treated and recurrence free (few exceptions apply)
  • Patients receiving any systemic chemotherapy (including chemotherapy received as the most recent anticancer therapy) or radiotherapy (except for palliative reasons) within 3 weeks prior to study randomised treatment
  • Persistent toxicities (>Common Terminology Criteria for Adverse Event () CTCAE grade 2) caused by previous cancer therapy, excluding CTCAE grade 2 peripheral neuropathy
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia (t-AML) or with features suggestive of MDS/AML
  • Patients with symptomatic uncontrolled
  • Major surgery within 2 weeks of starting study randomised treatment and patients must have recovered from any effects of any major surgery
  • Patients considered a poor medical risk
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1/OLAPARIB

    olaparib 300 mg oral tablets; twice daily

    Drug: OLAPARIB

  • Placebo comparator
    2/PLACEBO

    placebo matching olaparib 300 mg oral tablets; twice daily

    Drug: PLACEBO

Interventions

  • Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

  • DrugPLACEBO

    Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) using modified RECIST 1.1 in the cohort of patients with sBRCA ovarian cancer

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of progression free survival (PFS) using blinded independent central review (BICR)

    Time frame: From date of randomization until the date of first documented progression or date of death (by any cause, in the absence of disease progression) whichever came first, assessed up to 40 months

Secondary outcomes

  1. Progression Free Survival (PFS) using modified RECIST 1.1. in the Intent to Treat Population (ITT) consisting of all randomised patients with sBRCAm or HRR-associated gene mutations

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of progression free survival (PFS)using blinded independent central review (BICR)

    Time frame: From date of randomization until the date of first documented progression or date of death (by any cause, in the absence of disease progression), whichever came first, assessed up to 60 months

  2. Overall Survival (OS) in patients with sBRCAm ovarian cancer and in the ITT population consisting of all randomised patients

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of overall survival (OS)

    Time frame: From the date of randomisation until death due to any cause, assessed up to 60 months

  3. Time from randomisation to first subsequent therapy or death (TFST) in patients with sBRCAm ovarian cancer and in the ITT population consisting of all randomised patients

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of Time from randomisation to first subsequent therapy or death

    Time frame: From the date of randomisation to the earlier of first subsequent therapy start date, assessed up to 60 months

  4. Trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in sBRCA and HRR associated gene mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy

    To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL)

    Time frame: Administered at baseline, at day 29 then every 8 weeks (+/- 1 week) regardless of treatment discontinuation or disease progression, assessed up to 24 months

  5. Plasma mutation status

    To determine if p53, somatic BRCA and other HRR mutations are present in plasma prior to chemotherapy

    Time frame: cfDNA sample collected during pre-screening, assessed up to 40 months

  6. Time to earliest progression by RECIST 1.1 or CA-125 or Death in patients with sBRCAm ovarian cancer and in the ITT population consisting of all randomised patients

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of Time to earliest progression by RECIST 1.1 or CA-125 or Death. Progression or recurrence based on serum CA-125 levels will be defined on the basis of a progressive serial elevation of serum CA-125

    Time frame: From randomisation to the earliest date of investigator assesed RECIST or CA-125 progression or death by any cause, assessed up to 60 months

  7. Time from randomisation to second progression (PFS2) in patients with sBRCAm ovarian cancer and in the ITT population consisting of all randomised patients

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of Time from randomisation to second progression

    Time frame: From the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PRS or death, assessed up to 60 months

  8. Time from randomisation to second subsequent therapy or death (TSST) in patients with sBRCAm ovarian cancer and in the ITT population consisting of all randomised patients

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of Time from randomisation to second subsequent therapy of death

    Time frame: From the date of randomisation to the earlier of the date of second subsequent chemotherapy start date or death date, assessed up to 60 months

  9. Time from randomisation to study treatment discontinuation or death (TDT) in patients with sBRCAm ovarian cancer and in the ITT population consisting of all randomised patients

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by assessment of Time from randomisation to study treatment discontinuation or death

    Time frame: From the date of randomisation to the earlier of the date of study treatment discontinuation or death, assessed up to 60 months

Other outcomes

  1. Number of AEs in all patients who received at least one dose of randomised investigational product, olaparib or placebo

    To assess the safety and tolerability of olaparib maintenance monotherapy by assessment of AEs

    Time frame: assessed up to 60 months

  2. Changes in Vital signs in all patients who received at least one dose of randomised investigational product, olaparib or placebo

    To assess the safety and tolerability of olaparib maintenance monotherapy by assessment of vital signs

    Time frame: assessed up to 60 months

  3. Changes in Physical examination results in all patients who received at least one dose of randomised investigational product, olaparib or placebo

    To assess the safety and tolerability of olaparib maintenance monotherapy by assessment of physical examination parameters

    Time frame: assessed up to 60 months

  4. Changes in safety laboratory parameters in all patients who received at least one dose of randomised investigational product, olaparib or placebo

    To assess the safety and tolerability of olaparib maintenance monotherapy by safety laboratory (consisting of clinical chemistry and haematology)parameters assessment

    Time frame: assessed up to 60 months

07

Study locations

29 sites
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Stanford, California, United States
  • Research Site
    Augusta, Georgia, United States
  • Research Site
    Park Ridge, Illinois, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Covington, Louisiana, United States
  • Research Site
    Scarborough, Maine, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Albany, New York, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Goyang-si, Korea, Republic of
  • Research Site
    Seongnam-si, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Chiclayo, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Quezon City, Philippines
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Cambridge, United Kingdom
  • Research Site
    Coventry, United Kingdom
  • Research Site
    Edinburgh, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Oxford, United Kingdom
  • Research Site
    Sutton, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Jun 2019 and a completion of Jun 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2015
First posted
Mar 19, 2015
Start
Jul 2016
Primary completionEst.
Jun 2019
CompletionEst.
Jun 2019
Last update
May 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02392676
Lead sponsor
AstraZeneca
Collaborators
Myriad Genetic Laboratories, Inc.
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
Jul 2016
Primary completion
Jun 2019 (estimated)
Completion
Jun 2019 (estimated)
Last update
May 2, 2016

Study contacts

Charlie Gourley, Prof.
principal investigator · University of Edinburgh
Carol Aghajanian, MD
principal investigator · MSKCC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion